-
News | 2019.12.11
Anticipating and reacting quickly to outbreaks: a consortium won the Galien MedStartUp award
The Praesens Foundation, the Institut Pasteur, the Institut Pasteur de Dakar, University of Nebraska Medical Center and Twist Bioscience Corporation (NASDAQ: TWST) announced that the consortium is the winner of the Prix Galien MedStartUp award in the category: 'Best Collaboration Dedicated to the Developing or Underserved Populations Worldwide'. The consortium works together to...
-
Document de presse | 2022.10.30
Institut Pasteur Welcomes New, Comprehensive Relationship With UCSF QBI
Two Academic and Scientific Heavyweights Agree to Implement Joint Actions Towards the Creation of a Center of Excellence in Emerging Infectious Diseases with Planned Operations/Locations in Paris and San Francisco. In a ceremony on October 21, 2022, the Institut Pasteur and UC San Francisco Quantitative Biosciences Institute (UCSF QBI) announced a new partnership for the joint establishment...
-
News | 2023.01.27
Louis Pasteur Bicentenary Prize: five scientists honoured
As we celebrate the bicentenary of Louis Pasteur’s birth, the Institut Pasteur honoured five talented researchers. These prizes, given on January 26, 2023, reward achievements reflecting the “Pasteur ethos” in the fields of biomedical research, public health or innovation. The links between the Carlsberg Foundation and the Institut Pasteur date back to the end of the 19th century
-
Fiche maladie | 2019.10.16
Chikungunya
Chikungunya is a viral disease transmitted to humans by the bite of Aedes albopictus and Aedes aegypti mosquitoes. Although rarely fatal, chikungunya can cause significant pain and debilitating symptoms that affect patients' quality of life. Existing treatments are solely symptomatic. In France, the current conditions in 80% of départements are conducive to the emergence of chikungunya.
-
Article | 2017.09.12
Pasteur-Paris University enrollment 2018
The 2017-2018 call for enrollment of students in October 2018 is open.
-
Article | 2017.03.21
We need you
Making a donation to the Institut Pasteur means contributing to new breakthroughs in biomedical research and playing your own part in the work and discoveries of scientists.
-
Document de presse | 2017.12.14
Sanofi and the Institut Pasteur reward five researchers for their major contributions in the service of human health
Paris, France – December 13th 2017 - Sanofi and the Institut Pasteur presented the Sanofi - Institut Pasteur Awards for the sixth year in a row.Five internationally recognized researchers were rewarded for their work in two major fields with implications for global health: Immunology and Microbiology & Infection. The National Junior award winnersDocteur Fabrizia Stavru – Bacteria-Cell...
-
News | 2018.01.11
Frédéric Tangy, expert from the Institut Pasteur, talks about vaccines of today and tomorrow
In 2017, vaccinology expert Frédéric Tangy was recognized by the Institut Pasteur for his work on the Measles Platform and was elected as a member of the US National Academy of Inventors. As the Institut Pasteur enters its 130th year – it will be celebrating its 130th anniversary on November 14, 2018 – it seemed like a good opportunity to ask the scientist to tell us a little more about his...
-
Document de presse | 2019.01.24
The new Institut Pasteur strategic plan for 2019-2023
After taking office as President of the Institut Pasteur in January 2018, Professor Stewart Cole embarked on the development of a new strategic plan for the Institut Pasteur for the period 2019-2023. On December 21, 2018, the Board of Directors unanimously adopted this ambitious yet realistic action plan for the next five years.Three priority scientific areas have been identified: • emerging...
-
Document de presse | 2021.01.19
COVID-19: a lentiviral vaccine candidate for intranasal administration provides sterilizing protection in animal models
Scientists from the Institut Pasteur-TheraVectys Joint Laboratory recently published in Cell Host & Microbe1 the results of tests, in two preclinical models, of a COVID-19 vaccine candidate using a lentiviral vector administered by nasal route. Their study demonstrates that the vaccine candidate induces antibody response with strong neutralizing activity against SARS-CoV-2, as well as...
